12:00 AM
Jun 12, 2000
 |  BC Week In Review  |  Company News  |  Deals

Oxford BioMedica, Aventis deal

OXB expanded the companies' deal under which AVE has an exclusive worldwide license to OXB's hypoxia response element (HRE) for use...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >